跳至主要内容
临床试验/NCT03009422
NCT03009422Unknown不适用

Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis.

Tel-Aviv Sourasky Medical Center0 个研究点目标入组 20 人开始时间: 2014年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
20
主要终点
scar appearance

研究概览

简要总结

The investigators will compare the common treatment for cutaneous leishmaniasis with intra-lesional Pentostam to fractional CO2 laser with topical application of Pentostam.

Outcome will be final scar appearance assesd by two dermatologist and pain measurement by VAS.

详细描述

20 healthy patients diagnosed will cutaneous leishmaniasis with more than one lesion will be recruited.

Half of the lesions will be treated with intra-lesional injections of Pentostam, and the other half by CO2 laser with topical application of Pentostam.

Each lesion will recieve 3 treatments, one month apart between treatments. The patients will scale pain level of each treatment. Final scar appearance will be assessed by two dermatologists, without knowing what treatment was applied to each lesion.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Objective cutaneous leishmaniasis diagnosis.
  • More than one Lesion

排除标准

  • Previous treatment
  • Abnormal scarring

研究组 & 干预措施

Treatment

Experimental

CO2 fractional laser with local application of Pentostam

干预措施: fractional CO2 laser (Device)

Treatment

Experimental

CO2 fractional laser with local application of Pentostam

干预措施: Local application pentostam (Drug)

control

Active Comparator

Intra-lesinal Pentostam injedction

干预措施: intra-lisional pentostam (Drug)

结局指标

主要结局

scar appearance

时间窗: At sixth month

Each lesion will be photographed prior to treatment and at 6th month (Three months after last (3rd) treatment).Two dermatologist will asses each lesion outcome

次要结局

  • Pain assessed by VAS(at one month, two months, and three months)

研究者

申办方类型
Other Gov
责任方
Sponsor

相似试验

Fractional CO2 Laser With Topical Pentostam... | 临床试验